BioWorld Asia

Sep. 26, 2007

Study Shows European Biotech Investments Lagging Behind U.S.

BRUSSELS, Belgium - European biotechnology companies are being outpaced by their U.S. competitors in research investments and in the scale of their operations, according to a new study from the European Union. (BioWorld International) Read More

NIH Trial Of Diabetes Vaccine Boosts Shares Of Diamyd

New Selection Technique Signals Progress Toward Cell Therapy

Researchers Call Animal Models Biased In Stroke Assessments

Biolipox Gets Inflazyme Pipeline For C$4 Million Plus Milestones

Polyplus-transfection Enters RNAi Deal With Alnylam Pharma

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery

BioWorld Science

Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...